Loading...
XNAS
ACRS
Market cap688mUSD
Jul 09, Last price  
5.71USD
1D
3.63%
1Q
41.34%
Jan 2017
-78.96%
IPO
-48.33%
Name

Aclaris Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:ACRS chart
P/E
—
P/S
87.99
EPS
—
Div Yield, %
—
Shrs. gr., 5y
23.59%
Rev. gr., 5y
3.84%
Revenues
8m
-58.19%
00001,683,00010,091,0004,227,0006,482,0006,761,00029,752,00031,249,00018,720,0007,826,000
Net income
-65m
L-50.84%
-5,236,000-8,517,000-20,563,000-48,079,000-68,523,000-132,738,000-161,354,000-51,015,000-90,865,000-86,908,000-88,481,000-132,065,000-64,923,000
CFO
-47m
L+134.68%
-4,920,000-7,636,000-20,369,000-34,603,000-54,663,000-100,811,000-96,445,000-38,633,000-52,134,000-67,567,000-78,325,000-20,075,000-47,113,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
URL
https://www.aclaristx.com/
IPO date
Oct 07, 2015
Employees
100
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT